Tan Lab

Publications

Xia, M; Huang, P; Vago, FS; Jiang, W; Tan, M. Pseudovirus nanoparticles targeting the receptor binding HA1 domains of influenza viruses elicited high HA1-specific antibody responses and protected mice against mortality caused by influenza virus challenges. Vaccine. 2025; 46:126585.

Xia, M; Huang, P; Vago, FS; Jiang, W; Jiang, X; Tan, M. A Nanoparticle Comprising the Receptor-Binding Domains of Norovirus and Plasmodium as a Combination Vaccine Candidate. Vaccines. 2025; 13:34.

Huang, P; Xia, M; Vago, FS; Jiang, W; Tan, M. A Pseudovirus Nanoparticle Displaying the Vaccinia Virus L1 Protein Elicited High Neutralizing Antibody Titers and Provided Complete Protection to Mice against Mortality Caused by a Vaccinia Virus Challenge. Vaccines. 2024; 12:846.

Xia, M; Huang, P; Vago, F; Kawagishi, T; Ding, S; Greenberg, HB; Jiang, W; Tan, M. A Viral Protein 4-Based Trivalent Nanoparticle Vaccine Elicited High and Broad Immune Responses and Protective Immunity against the Predominant Rotaviruses. ACS Nano. 2024; 18:6673-6689.

Xia, M; Vago, F; Han, L; Huang, P; Nguyen, L; Boons, GJ; Klassen, JS; Jiang, W; Tan, M. The αTSR Domain of Plasmodium Circumsporozoite Protein Bound Heparan Sulfates and Elicited High Titers of Sporozoite Binding Antibody After Displayed by Nanoparticles. International Journal of Nanomedicine. 2023; 18:3087-3107.

Xia, M; Huang, P; Vago, F; Jiang, W; Tan, M. Pseudovirus Nanoparticles Displaying Plasmodium Circumsporozoite Proteins Elicited High Titers of Sporozoite-Binding Antibody. Vaccines. 2023; 11:1650.

Xia, M; López, K; Vago, FS; Huang, P; Auguste, DI; Jiang, W; Auguste, AJ; Tan, M. A bioengineered pseudovirus nanoparticle displaying SARS-CoV 2 RBD fully protects mice from mortality and weight loss caused by SARS-CoV 2 challenge. Biotechnology Journal. 2023; 18:e2300130.

Hensley, C; Nyblade, C; Zhou, P; Parreño, V; Ramesh, A; Frazier, A; Frazier, M; Garrison, S; Fantasia-Davis, A; Cai, R; Huang, PW; Xia, M; Tan, M; Yuan, L. Combined Live Oral Priming and Intramuscular Boosting Regimen with Rotarix® and a Nanoparticle-Based Trivalent Rotavirus Vaccine Evaluated in Gnotobiotic Pig Models of G4P[6] and G1P[8] Human Rotavirus Infection. Vaccines. 2023; 11:927.

Kawagishi, T; Sánchez-Tacuba, L; Feng, N; Costantini, VP; Tan, M; Jiang, X; Green, KY; Vinjé, J; Ding, S; Greenberg, HB. Mucosal and systemic neutralizing antibodies to norovirus induced in infant mice orally inoculated with recombinant rotaviruses. Proceedings of the National Academy of Sciences of USA. 2023; 120:e2214421120.

Nyblade, C; Hensley, C; Parreño, V; Zhou, P; Frazier, M; Frazier, A; Ramesh, A; Lei, S; Degiuseppe, JI; Tan, M; Yuan, L. A New Gnotobiotic Pig Model of P[6] Human Rotavirus Infection and Disease for Preclinical Evaluation of Rotavirus Vaccines. Viruses-Basel. 2022; 14:2803.

Rakau, K; Gededzha, M; Peenze, I; Huang, P; Tan, M; Steele, AD; Seheri, LM. The Association between Symptomatic Rotavirus Infection and Histo-Blood Group Antigens in Young Children with Diarrhea in Pretoria, South Africa. Viruses-Basel. 2022; 14:2735.

Xia, M; Huang, P; Tan, M. A Pseudovirus Nanoparticle-Based Trivalent Rotavirus Vaccine Candidate Elicits High and Cross P Type Immune Response. Pharmaceutics. 2022; 14:1597.

Han, Q; Xue, Z; Tan, M; Wang, L; Chen, H; Zhang, R. Bovine natural antibody IgM inhibits the binding of human norovirus protruding domain to its HBGA receptors. FEBS Open Bio. 2022; 12:1489-1497.

Wang, C; Kang, H; Tan, M; Cong, J; Su, D; Li, X; Chen, Y. Structural Insight into Terminal Galactose Recognition by Two Non-HBGA Binding GI.3 Noroviruses. Editor, Dutch RE. Journal of Virology. 2022; 96:e0042022.

Ison, MG; Tan, M; Daud, A; Huang, P; Jiang, JX. Quantitative norovirus viral load is not affected by home storage of stool. Transplant Infectious Disease. 2022; 24:e13826.

Xia, M; Hoq, MR; Huang, P; Jiang, W; Jiang, X; Tan, M. Bioengineered pseudovirus nanoparticles displaying the HA1 antigens of influenza viruses for enhanced immunogenicity. Nano Research. 2022; 15:4181-4190.

Tan, M. Norovirus Vaccines: Current Clinical Development and Challenges. Pathogens. 2021; 10:1641.

Jiang, X; Tan, M; Xia, M; Huang, P; Kennedy, MA. Intra-species sialic acid polymorphism in humans: a common niche for influenza and coronavirus pandemics?. Emerging Microbes and Infections. 2021; 10:1191-1199.

Xu, S; McGinnis, KR; Liu, Y; Huang, P; Tan, M; Stuckert, MR; Burnside, RE; Jacob, EG; Ni, S; Jiang, X; Kennedy, MA. Structural basis of P[II] rotavirus evolution and host ranges under selection of histo-blood group antigens. Proceedings of the National Academy of Sciences of USA. 2021; 118:e2107963118.

Zhou, HL; Chen, LN; Wang, SM; Tan, M; Qiu, C; Qiu, TY; Wang, XY. Prevalence and Evolution of Noroviruses between 1966 and 2019, Implications for Vaccine Design. Pathogens. 2021; 10:1012.

Zhaolei, X; Qi, H; Pengwei, H; Xi, J; Ming, T; Yaofeng, Z; Ning, L; Ran, Z. Characterization of Functional Components in Bovine Colostrum That Inhibit Norovirus Capsid Protruding Domains Interacting with HBGA Ligands. Pathogens. 2021; 10:857.

Wang, JX; Chen, LN; Zhang, CJ; Zhou, HL; Zhang, YH; Zhang, XJ; Hao, ZY; Qiu, C; Ma, JC; Zhao, YL; Zhong, W; Tan, M; Jiang, X; Wang, SM; Wang, XY. Genetic susceptibility to rotavirus infection in Chinese children: a population-based case-control study. Human Vaccines and Immunotherapeutics. 2021; 17:1803-1810.

Liu, C; Huang, P; Zhao, D; Xia, M; Zhong, W; Jiang, X; Tan, M. Effects of rotavirus NSP4 protein on the immune response and protection of the SR69A-VP8* nanoparticle rotavirus vaccine. Vaccine. 2021; 39:263-271.

Xia, M; Huang, P; Jiang, X; Tan, M. A Nanoparticle-Based Trivalent Vaccine Targeting the Glycan Binding VP8* Domains of Rotaviruses. Viruses-Basel. 2021; 13:72.